TITLE

Cost-Effectiveness of Recombinant Activated Factor VII as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients in Germany

AUTHOR(S)
Rossaint, Rolf; Christensen, Michael C.; Choong, Philip Iau Tsau; Boffard, Kenneth D.; Riou, Bruno; Rizoli, Sandro; Kluger, Yoram; Lefering, Rolf; Morris, Stephen
PUB. DATE
October 2007
SOURCE
European Journal of Trauma & Emergency Surgery;Oct2007, Vol. 33 Issue 5, p528
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The purpose of this study was to assess the cost-effectiveness of recombinant activated factor VII (rFVIIa) as adjunctive therapy for the control of bleeding in patients with severe blunt trauma injuries in Germany. The primary outcome measure was incremental cost per quality-adjusted life-year (QALY) gained. We developed a cost-effectiveness model based on patient-level data from a 30 day international, randomized, placebo-controlled phase II trial. The data were supplemented with secondary data from the German Trauma Register and German life tables to estimate lifetime costs and benefits. We assumed that the non-significant difference in mortality observed in the phase II trial of 5% in favor of rFVIIa could be verified in the ongoing, much larger follow-up trauma study. We adopted the perspective of third-party payers in Germany, and included all trauma-related healthcare costs. The incremental cost per QALY gained with rFVIIa relative to placebo was e29,451. The probability that this was below e30,000 and e40,000 was 51 and 58%, respectively. The estimates were sensitive to the differences observed in mortality and the applied discount rate. Based on preliminary evidence from a phase II trial, we conclude that, relative to placebo, rFVIIa may be a cost-effective therapy from the thirdparty payer perspective in Germany.
ACCESSION #
27035280

 

Related Articles

  • CARE FOR LOW-BACK PAIN.  // Massage & Bodywork;Sep/Oct2008, Vol. 23 Issue 5, p18 

    The article focuses on the study that asserts the cost effectiveness of naturopathic care in treating low-back pain. The study was administered to 75 patients whose age ranges from 18-65 who suffered low-back pain for six weeks that are randomly assigned to physiotherapy or naturopathic...

  • Questions and Answers.  // PharmacoEconomics;1998 Supplement 2, Vol. 14, p73 

    Presents questions and their answers related to diagnosis, treatment and cost of the treatment of diseases. Role of Helicobacter pylori in the pathogenesis of upper gastrointestinal disease (UGI); Studies that are being conducted to clarify the most cost-effective management of dyspepsia;...

  • On the probability of cost-effectiveness using data from randomized clinical trials. Willan, Andrew R. // BMC Medical Research Methodology;2001, Vol. 1, p8 

    Background: Acceptability curves have been proposed for quantifying the probability that a treatment under investigation in a clinical trial is cost-effective. Various definitions and estimation methods have been proposed. Loosely speaking, all the definitions, Bayesian or otherwise, relate to...

  • Cancer cost high in Germany.  // PharmacoEconomics & Outcomes News;4/19/2008, Issue 551, p2 

    The article discusses research being done on the cost of cancer treatment in Germany. It references a study by M. Hartmann. R. Kath and C. Gundermann published in the March 2008 issue of "Onkologie." The researchers mentioned the association of cancer treatment with higher costs per year of life...

  • NHS researchers back acupuncture.  // Pulse;11/29/2004, Vol. 64 Issue 47, p19 

    The article focuses on two studies which showed that acupuncture is costeffective for arthritis and osteoarthritis of the knee. A National Health Service-commissioned, multi centre study showed persistent, clinically relevant benefits for primary care patients with chronic headache. Acupuncture...

  • Cost-Effective Management of Nephrolithiasis. Slawson, David // American Family Physician;3/1/2005, Vol. 71 Issue 5, p971 

    Discusses research being done on treatment strategies for the management of nephrolithiasis. Reference to a study by Y. Lotan et al, published in a December 2004 issue of the "Journal of Urology"; Cost-effectiveness of conservative therapy in patients with first-time kidney stones; Effect of...

  • Oseltamivir cost effective for post-exposure prophylaxis of influenza.  // PharmacoEconomics & Outcomes News;5/6/2006, Issue 502, p4 

    The article discusses research being done on the cost effectiveness of post-exposure influenza prophylaxis with oseltamivir. It references a study by B. Sander et al published in a 2006 issue of "PharmacoEconomics." The methods and model used to evaluate the cost effectiveness of oseltamivir are...

  • The Essential Medicines List for a Global Patient Population. Robertson, J.; Hill, S. R. // Clinical Pharmacology & Therapeutics;Nov2007, Vol. 82 Issue 5, p498 

    Thirty years after its inception, the role, audience, and contents of the global Essential Medicines List (EML) are reviewed. Challenges for decision makers in applying the principles of medicine selection based on efficacy, safety, burden of disease, and cost effectiveness are discussed and...

  • The increasingly complex fourth hurdle for pharmaceuticals. Cohen, Joshua; Stolk, Elly; Niezen, Maartje // PharmacoEconomics;2007, Vol. 25 Issue 9, p727 

    There are three known criteria that underlie drug reimbursement decisions: therapeutic value, cost effectiveness and burden of disease. However, evidence from recent reimbursement decisions in several jurisdictions points to residual unexplained variables, one of which may be budget impact. An...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics